February 22, 2012 (Updated February 23, 2012) (Silver Spring, Maryland) — The Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee [1,2] voted overwhelmingly in favor of approving the obesity drug Qnexa (Vivus, Mountain View, CA), a combination of phentermine and controlled-release topiramate [3].

Specifically, the panel voted 20 to 2 in favor of approving Qnexa, stating that the risk/benefit ratio is appropriate in patients with a body-mass index (BMI) of >30 kg/m2 or >27 kg/m2 in patients with weight-related comorbidities. Despite some concerns over increases in heart rate, as well as concerns about potential birth defects in babies born to women taking the drug, particularly risks of cleft lip with or without palate, the panel felt the risks of untreated obesity outweighed these concerns.

孫銘聰醫師comment: 美國食品藥品監督管理局的內分泌新陳代謝藥物諮詢委員會,在考量了藥物的風險與好處後,以壓倒性的投票結果(20贊成,2反對),贊成通過QNEXA這個減肥藥物使用在BMI(體質量指數)大於等於30或BMI>27 且有體重相關的併發症的病患中。